Table 2 Description of empiric therapy *.
FACTOR | CASE FATALITY WITH FACTOR | CASE FATALITY WITHOUT FACTOR | RELATIVE RISK (95% CI) | P-VALUE |
|---|---|---|---|---|
Empiric by t = 0 | 7/29 (24%) | 9/50 (18%) | 1.34 (0.56-3.22) | NS |
Empiric by t = 8 hours | 12/48 (25%) | 4/31 (13%) | 1.94 (0.69-5.47) | NS |
Empiric by t = 24 hours | 14/68 (21%) | 2/11 (18%) | 1.13 (0.30-4.32) | NS |
Empiric by t = 48 hours | 15/74 (20%) | 1/5 (20%) | 1.01 (0.17-6.20) | NS |
Empiric at t > 48 hours | 0/3 (0%) | 16/76 (21%) | 0.00 | NS |
Never received empiric therapy. | 0/1 (0%) | 16/78 (21%) | ... | ... |
Empiric Treatment Class | Â | Â | Â | Â |
Carbapenem | 0/10 (0%) | 16/69 (24%) | 0.00 () | 0.09 |
Aminoglycoside | 1/7 (14%) | 15/72 (21%) | 0.67 (0.10-4.41) | NS |
Fluoroquinolone | 3/13 (23%) | 13/66 (20%) | 1.17 (0.39-3.54) | NS |
Beta-lactam/Beta-lactamase inhibitor combination | 6/16 (38%) | 10/63 (16%) | 2.36 (1.01-5.53) | 0.06 |
Cephalosporin | 5/30 (17%) | 11/49 (22%) | 0.74 (0.29-1.93) | NS |
Beta-lactam | 0/5 (0%) | 16/74 (22%) | 0.00 () | NS |